Skip to main content

Table 1 Basic characteristics of included studies

From: Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis

Source

Country/Area

Follow- up, M

Included Atropine Dose, %

Age, Year

Baseline Refraction, Diopter (Mean ± SD)

Experimental group

Control group

Total No. of Patients (test group/control group)

Chua et al., 2005 [10]

Singapore

12

1

6–12

−3.58 ± 1.17

1% Atropine

placebo

156/190

Hsiao et al., 2005 [11]

Taiwan

18

0.5

<18

−3.26 ± 0.15

0.5%Atropine+Multi-focal

Multi-focal lenses

66/61

Kumaran et al., 2015 [12]

Singapore

36

1

6–12

−3.36

1% Atropine

placebo

147/166

Polling et al., 2016 [13]

Europeans

12

0.5

<18

−6.6 ± 3.3

0.5% Atropine

placebo

60/17

Shih et al., 2001 [14]

Taiwan

18

0.5

6–13

−3.28 ± 0.13

0.5%Atropine+multi-focal

multi-focal glasses

66/61

Shin et al., 1999 [15]

Taiwan

12

0.5

6–13

−4.89 ± 2.06

0.5,0.25,0.1% Atropine

placebo

41/49

Wang et al., 2017 [16]

China

12

0.5

5–10

−1.3 ± 0.4

0.5% Atropine

placebo

63/63

Yam et al., 2018 [17]

China

12

0.05

4–12

−3.98 ± 1.69

0.05,0.025,0.01% Atropine

placebo

110/111

YEN et al., 1989 [18]

Taiwan

12

1

6–14

−1.523 ± 0.960

1% Atropine

placebo

32/32

Yi et al., 2015 [19]

China

12

1

7–12

−1.23 ± 0.32

1% Atropine

placebo

68/64